š° Single Arm Study News
Page 2 - Single Arm Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Single Arm Study. Real-time updates on events, politics, business and more.
December 8, 2022
/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and...
November 2, 2022
/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...
November 2, 2022
The second round of late-breaking clinical trial results were presented at VIVA22 on Nov. 1 in Las Vegas, NV.
September 14, 2022
Details on late-breaking clinical trials to be presented during The VEINS (VenousĀ EndovascularĀ INterventionalĀ Strategies) and VIVA (VascularĀ InterVentionalĀ Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.
September 1, 2022
/PRNewswire/ -- Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the...
November 4, 2021
/PRNewswire/ -- Sobiā¢ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021....
November 4, 2021
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- Sobi will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021. Sobi's commitment
November 4, 2021
/PRNewswire/ -- Sobiā¢ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021....
November 1, 2021
Milwaukee, WI (PRWEB) November 01, 2021 -- The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2021,
May 19, 2021
NOVARTIS AG CHF0.50(REGD) Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO ...